Program
SHR-9839
A development code. Also written as “SHR-9839(sc) for Injection”, “SHR-9839(sc) for Injection、Adebrelimab Injection、Paclitaxel for Injection、Cisplatin Injecion” and “SHR-9839(sc)”.
Its studies are mostly in Esophageal Squamous Cell Carcinoma · Squamous Cell Carcinoma of Head and Neck, led by Jiangsu HengRui Medicine.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu HengRui Medicine | 66 open or running | phase 2since Jun 2, 2024 | Apr 19, 2023 | Dec 2026phase 2 · NCT06915142 |
- Named in Jiangsu HengRui Medicine’s own pipeline as
SHR-9839 (sc)
, phase 2, as of Jul 31, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 19, 2023First study: phase 1 study in Advanced Solid TumorFirst studyNCT05836948 · 174 planned · China
- Jun 2, 2024Phase 2 study in Advanced Solid TumorsNCT06474455 · 156 planned · China
- Apr 1, 2025Phase 2 study in Advanced Malignant TumourNCT06915142 · 300 planned · China
- Jul 1, 2025Phase 2 study in Squamous Cell Carcinoma of Head and NeckNCT07059221 · 210 planned · China
- Nov 13, 2025Phase 2 study in Solid TumorNCT07229638 · 70 planned · China
- Aug 3, 2026Phase 2 study in Advanced Esophageal Squamous Cell CarcinomaNCT07751341 · 84 planned · China
Ahead
- Dec 2026Primary completion: phase 2 study in Advanced Malignant TumourNCT06915142
- Mar 2027Primary completion: phase 2 study in Squamous Cell Carcinoma of Head and NeckNCT07059221
- Apr 2027Primary completion: phase 2 study in Solid TumorNCT07229638
- Dec 2027Primary completion: phase 2 study in Advanced Esophageal Squamous Cell CarcinomaNCT07751341
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07751341Advanced Esophageal Squamous Cell Carcinoma · China | 2 | Recruiting | Dec 2027 | 84 |
| NCT07229638Solid Tumor · China | 2 | Recruiting | Apr 2027 | 70 |
| NCT07059221Squamous Cell Carcinoma of Head and Neck · China | 2 | Recruiting | Mar 2027 | 210 |
| NCT06915142Advanced Malignant Tumour · China | 2 | Recruiting | Dec 2026 | 300 |
| NCT06474455Advanced Solid Tumors · China | 2 | Recruiting | Jun 2029 | 156 |
| NCT05836948Advanced Solid Tumor · China | 1 | Recruiting | May 1, 2026 | 174 |
How it is read
Names in the registry
- “SHR-9839(sc) for Injection”, 1 entry
- “SHR-9839(sc) for Injection、Adebrelimab Injection、Paclitaxel for Injection、Cisplatin Injecion”, 1 entry
- “SHR-9839(sc)”, 1 entry
- “SHR-9839 for Injection”, 1 entry
- “SHR-9839 for Injection (sc)”, 1 entry
Codes read as this program: SHR9839.
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.